BRIEF-Oxford Biomedica and Sanofi amend Ocular licence terms

Mon Feb 17, 2014 2:20am EST

Related Topics

Feb 17 (Reuters) - Oxford BioMedica PLC : * And sanofi amend terms for ocular licence * Sanofi granted global rights across all ocular disease indications for

stargen and ushstat * Will regain the worldwide rights to encorstat, a treatment for corneal graft

rejection * Source text

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.